COMMUNIQUÉS West-GlobeNewswire

Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates
11/08/2025
Presented positive 6-month clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing [...]
Assertio Reports Second Quarter 2025 Financial Results
11/08/2025
Second Quarter Total Net Product Sales of $28.8 Million, Cash and Investments Increase to $98.2 Million Narrows Guidance on Continued Progress Implementing Long-Term Business Strategy LAKE FOREST, Ill., Aug. 11, 2025 ( [...]
BioVie Inc. Announces Closing of $12 Million Public Offering
11/08/2025
CARSON CITY, Nev., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions [...]
Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
11/08/2025
First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 trial ongoing, with [...]
TELA Bio Reports Second Quarter 2025 Financial Results
11/08/2025
MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial [...]
Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update
11/08/2025
- FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer - - Multiple U.S. clinical trials, including [...]
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update
11/08/2025
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be [...]
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
11/08/2025
Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launch DNL126 accelerated approval path for Sanfilippo [...]
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
11/08/2025
Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway Expected to Support [...]
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
11/08/2025
Net income of $1.6 million and $5.3 million for the three and six months ended June 30, 2025, respectively; reaffirms full-year revenue guidance of $118-128 million Ping Zhang, Executive Chairman, appointed interim CEO [...]
Xenon Reports Second Quarter 2025 Financial Results & Business Update
11/08/2025
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 – Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently [...]
Harrow Announces Second-Quarter 2025 Financial Results
11/08/2025
Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year period GAAP net income of $5.0 million Adjusted EBITDA of $17.0 million [...]
Standard BioTools Reports Second Quarter 2025 Financial Results
11/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the second quarter ended June 30, 2025. [...]
Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
11/08/2025
FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026 Planning continues for a Q1 2026 U.S. launch of Anaphylm, if approved by the FDA Company accelerates Anaphylm global expansion strategy to [...]
Olema Oncology Reports Second Quarter 2025 Financial and Operating Results
11/08/2025
Selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and for the OPERA-02 Phase 3 trial in combination with ribociclib OPERA-01 enrollment ongoing with top-line data expected in [...]

Pages